Welcome to our dedicated page for Nutriband news (Ticker: NTRBW), a resource for investors and traders seeking the latest updates and insights on Nutriband stock.
Overview of Nutriband Inc.
Nutriband Inc. (NASDAQ: NTRB, NASDAQ: NTRBW) is a U.S.-based pharmaceutical company headquartered in Oviedo, Florida. The company specializes in the development of innovative transdermal drug delivery systems, with a primary focus on addressing the global opioid crisis through its proprietary AVERSA™ abuse-deterrent technology. This technology is designed to incorporate aversive agents into transdermal patches to prevent the abuse, misuse, diversion, and accidental exposure of drugs with high abuse potential, such as opioids.
Core Technology: AVERSA™
The cornerstone of Nutriband’s operations is its patented AVERSA™ technology, which employs a proprietary aversive agent coating to deter oral abuse and accidental exposure. This innovation is particularly significant for transdermal drugs like fentanyl, which carry a high risk of misuse. The AVERSA™ platform has broad applications and can be integrated into various transdermal patches, enhancing the safety profile of essential medications while ensuring accessibility for patients in need.
Key Product: AVERSA™ Fentanyl
The company’s lead product under development is AVERSA™ Fentanyl, an abuse-deterrent fentanyl transdermal system. This product aims to be the world’s first abuse-deterrent opioid patch, addressing the dual challenges of opioid misuse and accidental exposure. AVERSA™ Fentanyl is being developed in collaboration with Kindeva Drug Delivery, a leading global contract development and manufacturing organization. The product is advancing through the U.S. FDA’s streamlined 505(b)(2) NDA regulatory pathway, which requires minimal clinical trials, potentially accelerating its time to market.
Intellectual Property and Global Reach
Nutriband’s AVERSA™ technology is protected by an extensive international intellectual property portfolio, with patents issued in 46 countries, including the United States, Europe, Japan, Korea, Russia, China, Canada, and Australia. This robust patent coverage positions the company to commercialize its technology on a global scale, ensuring competitive advantages in major pharmaceutical markets.
Revenue Streams and Market Presence
In addition to its pharmaceutical innovations, Nutriband generates revenue through its wholly-owned subsidiary, Pocono Pharma, which offers contract manufacturing services. The subsidiary specializes in kinesiology tape and other consumer transdermal products, supplying major retail chains such as Target, Walmart, Walgreens, and CVS. This diversified revenue model strengthens the company’s financial foundation while supporting its core R&D initiatives.
Strategic Collaborations
Nutriband has established strategic partnerships to advance its product pipeline. Its collaboration with Kindeva Drug Delivery ensures the scalability and commercial manufacturing capabilities required for AVERSA™ Fentanyl. Additionally, the company has licensed the use of Bitrex®, the world’s most bitter substance, as an aversive agent in its abuse-deterrent patches, further enhancing the effectiveness of its technology.
Market Significance
By addressing critical issues such as opioid misuse and accidental exposure, Nutriband positions itself as a key player in the abuse-deterrent pharmaceutical segment. The global market for such technologies is growing, driven by increasing regulatory focus on opioid safety and the need for innovative solutions to combat the opioid crisis. Nutriband’s AVERSA™ technology not only meets these demands but also sets a new standard for safety in transdermal drug delivery.
Conclusion
Nutriband Inc. is at the forefront of pharmaceutical innovation, leveraging its AVERSA™ technology to enhance patient safety and address pressing public health challenges. With its strong intellectual property portfolio, strategic collaborations, and diversified revenue streams, the company is well-positioned to make a significant impact in the pharmaceutical industry, particularly in the realm of abuse-deterrent drug delivery systems.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) reported financial results for the fiscal year ending January 31, 2023, highlighting a record revenue of $2.1 million, up 46% from the previous year. Key achievements include a favorable court verdict recovering 15% of total outstanding shares and the announcement of a Seven-for-Six Forward stock split. The company received patent allowance for its AVERSA™ technology in North America and partnered with Kindeva Drug Delivery for enhanced abuse-deterrent characteristics. Despite a net loss of $4.48 million (or $0.53 per share), down from $6.37 million in FY 2022, the results reflect significant operational progress. Research expenses increased to $0.98 million from $0.4 million, while SG&A expenses decreased slightly to $3.9 million. The company aims for commercial growth in 2023 and anticipates AVERSA™ to achieve annual sales between $80 million and $200 million.
Nutriband (NASDAQ:NTRB, NTRBW), recognized for its innovative transdermal solutions, is set to present at the Planet MicroCap Showcase: VEGAS 2023 on April 26, 2023, at 08:30 AM PST. CEO Gareth Sheridan will lead the presentation, followed by a Q&A session.
To join the live presentation, access the webcast here. For those interested in one-on-one investor meetings during the event in Las Vegas, registration is available here.
Nutriband is advancing its abuse deterrent fentanyl patch utilizing the patented AVERSA technology, aimed at mitigating drug misuse and exposure risks.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced a partnership with Kindeva Drug Delivery to advance the AVERSA™ Fentanyl formulation into commercial manufacturing. The AVERSA™ Fentanyl product utilizes Nutriband's proprietary abuse-deterrent technology and is projected to achieve peak U.S. sales between $80M and $200M. This collaboration aims to develop the first abuse-deterrent fentanyl patch, enhancing safety and accessibility for patients. The technology is supported by a robust intellectual property portfolio, with patents granted in multiple countries.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has secured a $2 million credit line to support the FDA approval process and commercial manufacturing of its lead product, AVERSA™ Fentanyl, an abuse-deterrent transdermal system. This technology combines Nutriband's proprietary methods with an FDA-approved fentanyl patch system, offering significant market potential, estimated at $80M - $200M in annual US sales. CEO Gareth Sheridan emphasized that this non-dilutive financing is crucial for their growth strategy and ongoing commercialization efforts. The AVERSA™ technology is backed by a robust intellectual property portfolio spanning multiple countries.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has announced its integration with Webull's Corporate Communications Service Platform, enhancing its investor relations and corporate communications capabilities. This partnership aims to boost Nutriband's visibility and engagement with current and potential investors by providing direct notifications of corporate news, earnings, and investor presentations. CEO Gareth Sheridan emphasized the importance of this platform for delivering timely and accurate information to shareholders. Nutriband is focused on developing transdermal pharmaceutical products, including an abuse deterrent fentanyl patch using its advanced AVERSA™ technology.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced on March 2, 2023, that Alan Smith, Ph.D., COO and President of its subsidiary, 4P Therapeutics, was appointed to the FDA's Center for Research on Complex Generics Stakeholder Expert Committee on Adhesion Testing for transdermal delivery systems. This committee aims to enhance collaboration between the FDA and industry for developing safe generic products. Dr. Smith brings over 25 years of expertise in transdermal drug delivery systems. Nutriband focuses on developing innovative transdermal products, including its abuse-deterrent fentanyl patch, using proprietary AVERSA™ technology.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced it has completed the necessary steps to submit its application to Ecuador's Health Register, allowing for the distribution of medical devices and cosmetic products in South America. This move opens access to the Andean Community, which includes four countries: Colombia, Ecuador, Peru, and Bolivia, with a combined population exceeding 114 million. Nutriband is focused on developing transdermal pharmaceutical products, including its lead product, an abuse-deterrent fentanyl patch utilizing AVERSA™ technology. The company is navigating various risks associated with product development and regulatory approvals.
FAQ
What is the current stock price of Nutriband (NTRBW)?
What does Nutriband Inc. specialize in?
What is AVERSA™ technology?
What is Nutriband’s lead product?
Where is Nutriband’s technology patented?
How does Nutriband generate revenue?
Who are Nutriband’s strategic partners?
What challenges does Nutriband face?
What makes Nutriband unique in the pharmaceutical industry?
